An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and I in a 4 week on, 2 week off schedule in patients with advanced solid tumors.

被引：0
|
作者：
Eskens, F. A.
Planting, A.
Van Doorn, L.
Isoe, T.
Hayashi, K.
Hussain, S.
Ekman, L.
Burger, H.
Verweij, J.
机构：
[1] Erasmus MC, Rotterdam, Netherlands
[2] Kirin Co Ltd, Tokyo, Japan
[3] Quintiles, Uppsala, Sweden
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：87S / 87S
页数：1
相关论文
共 50 条
  • [21] Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
    Minami, Hironobu
    Ando, Yuichi
    Ma, Brigette Buig Yue
    Lee, Jih-Hsiang
    Momota, Hiroyuki
    Fujiwara, Yutaka
    Li, Leung
    Fukino, Koichi
    Ito, Koji
    Tajima, Takeshi
    Mori, Asuka
    Lin, Chia-Chi
    CANCER SCIENCE, 2016, 107 (10) : 1477 - 1483
  • [22] A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors.
    Papadopoulos, K. P.
    Mendelson, D. S.
    Tolcher, A. W.
    Patnaik, A.
    Burris, H. A.
    Rasco, D. W.
    Bendell, J. C.
    Gordon, M. S.
    Kato, G.
    Wong, H.
    Bomba, D.
    Lee, S.
    Gillenwater, H. H.
    Woo, T.
    Infante, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors.
    Johnson, Melissa Lynne
    Cosaert, Jan G. C. E.
    Falchook, Gerald Steven
    Jones, Suzanne Fields
    Strickland, Donald
    Greenlees, Carol
    Charlton, Julie
    MacDonald, Alexander
    Overend, Philip
    Adelman, Carrie
    Burris, Howard A.
    Pease, Elizabeth J.
    Patel, Gargi Surendra
    Wang, Judy Sing-Zan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] A phase 1 dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumors.
    Plummer, R
    Vidal, L
    Perrett, R
    Shaw, H
    Pilkington, M
    Hanwell, J
    Temple, G
    Fong, P
    Amelsberg, A
    Calvert, H
    de Bono, J
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8990S - 8990S
  • [25] A phase I, open-label dose-escalation trial of weekly (qw) BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking Nanobody, in patients (pts) with advanced/metastatic solid tumors.
    Isambert, Nicolas
    Elez, Elena
    Zanetta, Sylvie
    Matos, Ignacio
    Nazabadioko, Serge
    Xue, Wenqiong
    Carriere, Philippe
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.
    Ho, A. L.
    Bendell, J. C.
    Cleary, J. M.
    Schwartz, G. K.
    Burris, H. A.
    Oakes, P.
    Agbo, F.
    Barker, P. N.
    Senderowicz, A. M.
    Shapiro, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] A phase I, open-label, multicenter dose escalation study to assess the safety, tolerability, and pharmacokinetics of AZD2811 nanoparticle in patients with advanced solid tumors.
    Johnson, Melissa Lynne
    Wang, Judy Sing-Zan
    Falchook, Gerald Steven
    Charlton, Julie
    MacDonald, Alexander
    Strickland, Donald
    Jones, Suzanne Fields
    Pease, Elizabeth J.
    Brugger, Wolfram
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.
    Kollmannsberger, Christian K.
    Sharma, Sunil
    Shapiro, Geoffrey
    Chi, Kim N.
    Christensen, James
    Tassell, Vanessa Roberts
    Chao, Richard C.
    Faltaos, Demiana
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label,phase Ⅰ dose escalation and dose expansion trial
    Yan Song
    Jinwan Wang
    Xiubao Ren
    Jie Jin
    Li Mao
    Chris Liang
    Lieming Ding
    Lin Yang
    ChineseJournalofCancerResearch, 2021, 33 (01) : 103 - 116
  • [30] Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors.
    Hong, D. S.
    Koetz, B. S.
    Kurzrock, R.
    Senzer, N. N.
    Hanekom, W.
    Naing, A.
    Wheler, J. J.
    Mink, J.
    Ren, M.
    Nemunaitis, J. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345